Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.62EUR
10:30am GMT
Change (% chg)

€-0.41 (-0.55%)
Prev Close
€75.03
Open
€75.05
Day's High
€75.31
Day's Low
€74.31
Volume
575,701
Avg. Vol
2,040,131
52-wk High
€92.97
52-wk Low
€72.63

Select another date:
Photo

France's Sanofi pins hopes on new drugs after setbacks

PARIS French pharmaceuticals group Sanofi said on Wednesday it had suffered from low uptake for a new cholesterol drug and from concerns about a dengue vaccine, but expressed confidence its pipeline of new products would support long-term growth.

France's Sanofi pins hopes on new drugs after setbacks

PARIS French pharmaceuticals group Sanofi said on Wednesday it had suffered from low uptake for a new cholesterol drug and from concerns about a dengue vaccine, but expressed confidence its pipeline of new products would support long-term growth.

Sanofi CEO says M&A targets in oncology are 'very expensive'

PARIS Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very expensive".

Sanofi CEO says M&A targets in oncology are 'very expensive'

PARIS Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very exensive".

Sanofi CEO says M&A targets in oncology are "very expensive"

PARIS, Dec 13 Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very exensive".

UPDATE 3-France's Sanofi pins hopes on new drugs after setbacks

* CEO says company on track to sell European generics unit (Adds details, updates shares)

Sanofi sees 9 regulatory submissions over next 18 months

PARIS, Dec 13 Sanofi said on Wednesday it saw its pipeline of new drugs supporting growth in the long term, and plans to file 9 regulatory applications over the next 18 months.

BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous Squamous Cell Carcinoma

* REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

Sanofi investors hungry for drug progress and deal news

PARIS, Dec 12 Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.

FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

Select another date: